Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2023)

Cullinan Therapeutics has reported Cash from Operations over the past 4 years, most recently at 18131000.0 for Q4 2023.

  • Quarterly results put Cash from Operations at 18131000.0 for Q4 2023, up 27.43% from a year ago — trailing twelve months through Dec 2023 was 134275000.0 (down 6.01% YoY), and the annual figure for FY2025 was 175750000.0, down 20.95%.
  • Cash from Operations for Q4 2023 was 18131000.0 at Cullinan Therapeutics, up from 34141000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CGEM hit a ceiling of 1515000.0 in Q1 2021 and a floor of 54353000.0 in Q3 2022.
  • Median Cash from Operations over the past 4 years was 17163500.0 (2021), compared with a mean of 20884000.0.
  • Biggest five-year swings in Cash from Operations: skyrocketed 69.79% in 2021 and later crashed 1346.07% in 2022.
  • Cullinan Therapeutics' Cash from Operations stood at 9436000.0 in 2020, then tumbled by 60.78% to 15171000.0 in 2021, then crashed by 64.68% to 24983000.0 in 2022, then increased by 27.43% to 18131000.0 in 2023.
  • The last three reported values for Cash from Operations were 18131000.0 (Q4 2023), 34141000.0 (Q3 2023), and 31006000.0 (Q2 2023) per Business Quant data.